Regulatory approval for the use of ICIs is limited to a specific threshold of PD-L1 expression in some tumor types (e.g., non-small cell lung cancer, cervical, bladder cancer or triple negative breast cancer) [102]. This evidence concerns the gene CD274 and neoplasm.